PET/CT Imaging in Oncology: Clinical Updates and Perspectives
This reprint focuses on the most recent advances in PET/CT imaging within the field of oncology. These innovations include studies on novel or experimental tracers, such as [18F]FES for the imaging of advanced breast cancer and [68Ga]Ga-Nitroimidazole for visualizing hypoxic tumour components; resea...
Saved in:
| Other Authors: | , |
|---|---|
| Format: | Electronic Book Chapter |
| Language: | English |
| Published: |
Basel
MDPI - Multidisciplinary Digital Publishing Institute
2023
|
| Subjects: | |
| Online Access: | DOAB: download the publication DOAB: description of the publication |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
| LEADER | 00000naaaa2200000uu 4500 | ||
|---|---|---|---|
| 001 | doab_20_500_12854_128809 | ||
| 005 | 20231130 | ||
| 003 | oapen | ||
| 006 | m o d | ||
| 007 | cr|mn|---annan | ||
| 008 | 20231130s2023 xx |||||o ||| 0|eng d | ||
| 020 | |a books978-3-0365-9451-4 | ||
| 020 | |a 9783036594507 | ||
| 020 | |a 9783036594514 | ||
| 040 | |a oapen |c oapen | ||
| 024 | 7 | |a 10.3390/books978-3-0365-9451-4 |c doi | |
| 041 | 0 | |a eng | |
| 042 | |a dc | ||
| 072 | 7 | |a M |2 bicssc | |
| 100 | 1 | |a Piccardo, Arnoldo |4 edt | |
| 700 | 1 | |a Fiz, Francesco |4 edt | |
| 700 | 1 | |a Piccardo, Arnoldo |4 oth | |
| 700 | 1 | |a Fiz, Francesco |4 oth | |
| 245 | 1 | 0 | |a PET/CT Imaging in Oncology: Clinical Updates and Perspectives |
| 260 | |a Basel |b MDPI - Multidisciplinary Digital Publishing Institute |c 2023 | ||
| 300 | |a 1 electronic resource (180 p.) | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 506 | 0 | |a Open Access |2 star |f Unrestricted online access | |
| 520 | |a This reprint focuses on the most recent advances in PET/CT imaging within the field of oncology. These innovations include studies on novel or experimental tracers, such as [18F]FES for the imaging of advanced breast cancer and [68Ga]Ga-Nitroimidazole for visualizing hypoxic tumour components; research on new radiopharmaceuticals represents, in fact, one the most important study fields of PET research. Advanced image analysis, such as radiomics, is also featured in this reprint; this method has been applied to both traditional nuclear medicine clinical issues, such as thyroid nodules, as well as in the setting of new therapeutic approaches, such as CAR-T cell therapy. Finally, the theranostic implications of PET radiotracers and the diagnostic processes of rare tumours are explored in this reprint. | ||
| 540 | |a Creative Commons |f https://creativecommons.org/licenses/by/4.0/ |2 cc |4 https://creativecommons.org/licenses/by/4.0/ | ||
| 546 | |a English | ||
| 650 | 7 | |a Medicine |2 bicssc | |
| 653 | |a thyroid incidentalomas | ||
| 653 | |a radiomics | ||
| 653 | |a texture analysis | ||
| 653 | |a 18F-FDG | ||
| 653 | |a PET/CT | ||
| 653 | |a positron emission tomography | ||
| 653 | |a thyroid cancer | ||
| 653 | |a cervical cancer | ||
| 653 | |a hypoxia | ||
| 653 | |a 68Ga-Nitroimidazole | ||
| 653 | |a HIF-1α | ||
| 653 | |a immunohistochemistry | ||
| 653 | |a Mantle Cell Lymphoma | ||
| 653 | |a MTV | ||
| 653 | |a TLG | ||
| 653 | |a sarcopenia | ||
| 653 | |a diffuse-large B cell lymphoma | ||
| 653 | |a chimeric antigen receptor T cells | ||
| 653 | |a response assessment | ||
| 653 | |a computed tomography | ||
| 653 | |a paraneoplastic syndromes | ||
| 653 | |a neurooncology | ||
| 653 | |a [18F]FDG PET/CT | ||
| 653 | |a PNS | ||
| 653 | |a FDG | ||
| 653 | |a FES | ||
| 653 | |a breast cancer | ||
| 653 | |a oestrogen receptor | ||
| 653 | |a diagnosis | ||
| 653 | |a nuclear medicine | ||
| 653 | |a meningioma | ||
| 653 | |a peptide receptor radionuclide therapy | ||
| 653 | |a PRRT | ||
| 653 | |a targeted therapy | ||
| 653 | |a somatostatin receptor | ||
| 653 | |a SSTR | ||
| 653 | |a n/a | ||
| 653 | |a solitary fibrous tumor | ||
| 653 | |a hemangiopericytoma | ||
| 653 | |a fluorodeoxyglucose | ||
| 653 | |a fluorocholine | ||
| 653 | |a non-FDG radiopharmaceuticals | ||
| 653 | |a [18F]FDG PET/MRI | ||
| 653 | |a multiparametric imaging | ||
| 653 | |a dual-time-point kinetic | ||
| 653 | |a cervical carcinoma | ||
| 653 | |a lymph node metastases | ||
| 653 | |a PSMA hybrid imaging | ||
| 653 | |a staging of primary prostate cancer | ||
| 653 | |a [18F]PSMA-1007 | ||
| 653 | |a [68Ga]Ga-PSMA-11 | ||
| 653 | |a SUVmax cut-off level | ||
| 653 | |a prostate carcinoma | ||
| 653 | |a intra-tumoural heterogeneity | ||
| 653 | |a intrahepatic cholangiocarcinoma | ||
| 653 | |a positron emission tomography-computed tomography | ||
| 653 | |a immunology | ||
| 653 | |a FGFR2 translocation | ||
| 653 | |a imaging fusion | ||
| 653 | |a navigation technology | ||
| 653 | |a immunotherapy | ||
| 653 | |a Hodgkin lymphoma | ||
| 653 | |a FDG-PET | ||
| 653 | |a pseudoprogression | ||
| 653 | |a LYRIC | ||
| 653 | |a whole-body | ||
| 653 | |a dynamic PET | ||
| 653 | |a parametric FDG | ||
| 653 | |a Patlak | ||
| 856 | 4 | 0 | |a www.oapen.org |u https://mdpi.com/books/pdfview/book/8276 |7 0 |z DOAB: download the publication |
| 856 | 4 | 0 | |a www.oapen.org |u https://directory.doabooks.org/handle/20.500.12854/128809 |7 0 |z DOAB: description of the publication |